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Purpose of the study
Fractional clearance rate of apolipoprotein B100-contain-
ing lipoproteins is reduced in HIV infection before and
after antiretroviral (ARV) treatment [1]. We compared
lipoprotein lipase (LPL) activity and gene expression in
HIV-positive subjects before and 6 months after ARV with
HIV-negative controls.
Methods
Fasting blood post heparin total and hepatic lipase activ-
ity, adiponectin, leptin, insulin, glucose, and lipid meas-
urements were made in 32 HIV-infected and 15 HIV-
negative controls. LPL was estimated by subtracting
hepatic lipase from total lipase. Adiponectin, LPL and
hormone sensitive lipase (HSL) gene expression were
measured from iliac crest subcutaneous fat biopsies.
Patients were tested before, and 6 months after randomi-
sation to AZT/3TC (n = 15) or TDF/FTC (n = 17) with EFV.
Between-group comparison was by Mann-Whitney and
paired samples by the Wilcoxon signed rank tests.
Summary of results
There were no differences in gender, ethnicity, baseline
BMI, regional fat distribution (whole body DEXA) and
visceral (VAT) and subcutaneous fat (SAT) measured by
abdominal CT scans between controls and patients. Trunk
fat/BMI ratio, VAT and VAT:SAT ratio significantly
increased after 6-month ARV therapy (p = 0.01). There
were no differences between groups in serum NEFA,
HOMA and leptin levels. Selected other results are shown
in Table 1.
Conclusion
Post heparin lipoprotein lipase activity is reduced in HIV
and does not return to control levels after 6 months of
ARV therapy. AZT-containing regimens are associated
with a greater increase in LPL, LPL gene expression and
plasma adiponectin than TDF.
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Table 1: Measurements are mean (+/- SD). RNA expressions are in arbitrary units. * control vs. HIV naïve, ** control vs. HIV 6 mth *** 
HIV naïve vs. HIV 6 mth.
Control HIV Naive HIV AZT 6 m HIV TDF 6 m p all HIV 6 m
Adiponectin ug/ml 8.2 (4.9) 10.3 (4.1) 13.3 (6.8) **p = 0.025, ***p = 
0.05
9.4 (3.3) **0.04, ***0.01
Hepatic lipase nmol/ml/h 200 (119) 126 (80) 148 (110) 137 (93) NS
LPL nmol/ml/h 528 (151) 297 (107) *p = 0.0001 382 (212) **p = 0.05, ***p = 
0.05
341 (167) **p = 0.12 **0.008
LPL mRNA 173 (106) 188 (97) 187 (68) **p = 0.05 167 (114) **NS **0.004, ***0.007
HSL mRNA 0.38 (0.29) 0.38 (0.29) 1.2 (1.5) **p = 0.05, ***p = 
0.05
1.3 (1.6) **p = 0.02, ***p = 
0.015
**0.02, ***0.001
Adiponectin mRNA 30.9 (25.4) 26.1 (9.1) 39.4 (20.1) ***p = 0.09(NS) 33.2 (10.8) ***p = NS NSPage 2 of 2
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